Abstract Details

<< Back to Schedule

9/27/2014  |   10:45 AM - 12:00 PM   |  Ballroom A-B

Plenary V
Is Universal Newborn Screening for Congenital Cytomegalovirus Good Public Health Policy?

During the past 20 years much has been learned about the incidence, natural history, prevention, and treatment of congenital cytomegalovirus (cCMV) – but many questions remain. Given the consequences of cCMV for many children, one obvious question is whether it would be good public health policy to screen all newborns for cCMV. Addressing this question requires consideration of details related to whether screening should be done based on saliva, urine, or dried bloodspots and how the mechanics of screening should be organized (e.g., who should do it, where it should be done, what additional infrastructure would be required, who will pay for it). Considering the Wilson and Jungner 1968 criteria for when screening should be done, each member of the panel will be given 7 minutes to summarize his or her recommendations about whether newborn screening for cCMV should be done for all newborns. If yes, how should it be done? If no, why not? In either case, what additional research/information is needed to facilitate effective screening? Following the recommendations by each panel member, the moderator (Dr. Michael Cannon from the CDC) will pose questions for the panel members to discuss.

Michael Cannon (Primary Presenter), mcannon@cdc.gov;
Michael Cannon is a research epidemiologist at the National Center on Birth Defects and Developmental Disabilities.

ASHA DISCLOSURE:

Financial - No relevant financial relationship exist.

Nonfinancial - No relevant nonfinancial relationship exist.

Mark Schleiss (Primary Presenter), schleiss@umn.edu;
co-author

ASHA DISCLOSURE:

Financial - No relevant financial relationship exist.

Nonfinancial - No relevant nonfinancial relationship exist.

Karen B. Fowler (Primary Presenter), kfowler@uab.edu;
Dr. Fowler is a Professor in the Division of Infectious Diseases in the Department of Pediatrics and the Co-Director of the NIDCD CHIMES Study.

ASHA DISCLOSURE:

Financial - Receives Grants for Employment from NIH grant to UAB.  

Nonfinancial - No relevant nonfinancial relationship exist.

William Rawlinson (Co-Presenter), w.rawlinson@unsw.edu.au;
Dr. William Rawlinson is the Director of Virology, Department of Microbiology SEALS, with a conjoint position in the Department of Infectious Diseases, Prince of Wales Hospital. He is Professor in the faculties of Medicine and Science at UNSW, currently supervising PhD students researching CMV diagnosis, CMV antiviral resistance in transplantation, and testing for blood borne viruses (BBV) in transplantation. He has studied CMV infection in different settings since completing his PhD in the molecular biology of CMV. Most recently these studies have been of the adverse consequences of CMV in at-risk populations, using in vitro models. The Diagnostic Virology Laboratory he heads provides a range of molecular assays for CMV including antiviral resistance testing, and most recently ganciclovir levels using mass spectrometry. He consults on viral infections and general infectious diseases at Prince of Wales, Sydney Children’s and the Royal Hospital for Women.

ASHA DISCLOSURE:

Financial - No relevant financial relationship exist.

Nonfinancial - No relevant nonfinancial relationship exist.

Presentation:
476Karen B.Fowler.pdf
476MarkSchleiss_x.pdf
476MichaelCannon_x.pdf
476WilliamRawlinson_x.pdf

Handouts:
No handouts have been uploaded.